Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes

Table 1

FACS analysis of baseline 4T1 TDLNs and after culture activation of the L-selectin^low subpopulation.

	CD4	CD8	THY1.2	L-sel	CD11b	CD11c	B220
	(% (SD))	(% (SD))	(% (SD))	(% (SD))	(% (SD))	(% (SD))	(% (SD))
Day 0: all cells	36.5	19.5	56.4	29.7	3.6	1.2	42.6
	(7.0)	(3.7)	(4.5)	(11.6)	(0.9)	(1.1)	(1.1)
Day 0: CD62L-low	27.74	6.0	35.6	1.4	6.7	3.5	55.3
	(9.5)	(2.2)	(9.1)	(0.6)	(2.1)	(3.2)	(16.4)
Day 0: CD62L-high	46.3	24.1	66.7	25.6	1.73	2.12	39.0
	(6.3)	(4.8)	(9.5)	(9.9)	(1.3)	(3.7)	(9.3)
Day 5: CD62L-low	33.3	20.9	59.6	1.6	1.6	0.9	46.8
	(4.4)	(8.5)	(6.8)	(0.8)	(1.1)	(0.2)	(13.4)

4T1 TDLNs contain approximately 30% of cells that demonstrate downregulation of CD62L suggestive of antigen-priming in vivo. The L-selectin^low subpopulation contains higher proportions of CD4 prior to culture activation and consists predominantly of Thy1.2+ lymphocytes after ex vivo expansion. Each experiment was performed 5 times.